3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
37
Lung Neoplasms
20
Carcinoma, Hepatocellular
18
Breast Neoplasms
16
Small Cell Lung Carcinoma
14
Urinary Bladder Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
7
Liver Neoplasms
7
Neoplasm Metastasis
6
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Ovarian Neoplasms
5
Neoplasms
5
Endometrial Neoplasms
5
Carcinoma, Transitional Cell
5
Carcinoma, Renal Cell
5
Carcinoma
5
Biliary Tract Neoplasms
5
Stomach Neoplasms
4
Melanoma
4
Colorectal Neoplasms
4
Cholangiocarcinoma
4
Prostatic Neoplasms
3
Neoplasms by Site
3
Esophageal Neoplasms
3
Carcinoma, Squamous Cell
3
Uterine Cervical Neoplasms
2
Turcot syndrome
2
Thyroid Neoplasms
2
Thoracic Neoplasms
2
Interventions
pembrolizumab
4
Oxaliplatin
4
zolbetuximab
2
camrelizumab
2
apatinib
2
S 1 (combination)
2
Paclitaxel
2
Nivolumab
2
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
tislelizumab
1
tepotinib
1
relugolix
1
regorafenib
1
lenvatinib
1
durvalumab
1
dabrafenib
1
cemiplimab
1
cabazitaxel
1
alpha-2'-deoxythioguanosine
1
X-Rays
1
Vinorelbine
1
Trifluridine
1
Surveys and Questionnaires
1
Ramucirumab
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Radiosurgery
1
Radiation
1
Proton Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Adenocarcinoma
×
durvalumab
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled